Healthcare ❯Pharmaceuticals

Vaccine Development

Clinical Trials COVID-19 Vaccines Nasal Spray Vaccines Bavarian Nordic Covid-19 Vaccine Approval Emergency Use Authorization Covid-19 AstraZeneca Market Impact Vaccine Safety Market Competition mRNA Vaccines Vaccine Efficacy Future Vaccines

Moderna Cuts 2025 Revenue Forecast by $1 Billion, Shares Drop Over 20%

The biotech firm cites declining COVID-19 vaccine demand, slow RSV vaccine adoption, and increased competition as key challenges.

BioNTech and Pfizer Agree to $1.2 Billion Settlement Over U.S. Vaccine Patent Disputes

FDA Approves First At-Home Nasal Spray Flu Vaccine

FDA Approves First At-Home Nasal Spray Flu Vaccine

Health Canada Approves Moderna's Updated COVID-19 Vaccine

Moderna to Cut $1.1 Billion in R&D Spending as Vaccine Sales Decline

FDA Expands Approval of GSK's RSV Vaccine to Adults Aged 50-59